Opendata, web and dolomites

iHEAR SIGNED

Gene therapy of inherited and acquired hearing loss

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 iHEAR project word cloud

Explore the words cloud of the iHEAR project. It provides you a very rough idea of what is the project "iHEAR" about.

opportunity    viral    people    caused    genome    human    safety    optimized    transduction    ipsc    translatable    world    spiral    treat    editing    proteins    models    vivo    therapeutic    protect    wp3    strategies    tools    expression    model    causative    transgene    social    inherited    toolbox    mirnas    lentiviral    fluorescent    vitro    promoters    appropriate    sgn    mouse    burden    demonstrated    stem    impaired    efficiency    wp1    otic    alterations    whom    transfer    designs    proper    congenital    configurations    generate    mutations    hair    samples    therapy    primary    constructs    wp2    inducible    hc    explored    lines    experiments    efficient    million    cells    aav    precision    financial    murine    employed    adeno    acquired    performing    proof    patient    translatability    pluripotent    incl    protective    perform    ear    neurons    genes    vectors    inner    corrective    correct    medicine    children    monogenetic    hearing    substantial    receptor    gene    360    ganglion    600    marker    clinically    collection    vector    patients    once    cell    treatment   

Project "iHEAR" data sheet

The following table provides information about the project.

Coordinator
MEDIZINISCHE HOCHSCHULE HANNOVER 

Organization address
address: Carl-Neuberg-Strasse 1
city: HANNOVER
postcode: 30625
website: www.mh-hannover.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙999˙500 €
 EC max contribution 1˙999˙500 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-COG
 Funding Scheme ERC-COG
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2024-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) coordinator 1˙999˙500.00

Map

 Project objective

To address the substantial financial and social burden caused by hearing loss in 360 million people world-wide, I aim to improve hearing via gene therapy to correct inherited and protect from acquired hearing loss. In vitro experiments will establish the best vector configurations for transfer of therapeutic genes and miRNAs into inner ear hair cells (HC) and spiral ganglion neurons (SGN). The efficiency of the best-performing vector designs will then be explored in vivo using fluorescent marker proteins. Cell-type specific and inducible promoters as well as receptor-targeted vectors will be employed as a safety measure and to ensure transgene expression in HC and SGN target cells. Once efficient transduction of appropriate target cells and proper expression of therapeutic proteins are demonstrated, I will perform proof-of-concept studies in hearing loss models, incl. established mouse models, to correct (WP1) or protect (WP2) from impaired hearing. To ensure translatability of these findings, I will generate human induced pluripotent stem cells (iPSC) from patients with hearing loss (WP3), so that I can test optimized constructs in human otic cells. Moreover, I have access to a collection of well-characterized samples from over 600 hearing loss patients, including children with congenital hearing loss in whom many novel monogenetic alterations were identified. These resources provide the unique opportunity to generate a novel toolbox for the treatment of hearing loss. In addition to lentiviral and adeno-associated viral (AAV) vector delivery of corrective or protective genes to treat hearing loss, I will apply state-of-the-art genome editing tools to model and correct mutations causative for hearing loss in cell lines, primary cells from murine models, human patients and patient-derived iPSC. This work will contribute to development of clinically translatable approaches for precision medicine strategies to improve hearing loss treatment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IHEAR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IHEAR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

SmartForests (2020)

Smart Forests: Transforming Environments into Social-Political Technologies

Read More  

UEMHP (2019)

Unravelling Earth’s magnetic history and processes

Read More  

DYNAPOL (2019)

Modeling approaches toward bioinspired dynamic materials

Read More